Posted on 18/11/2009 in Pharmaceutical Company Product News
Eisai has launched its latest therapy this week - the Lusedra (fospropofol disodium) injection.
The treatment is designed for use in patients in need of an intravenous sedative-hypnotic agent.
It is to be used by healthcare professionals trained in the administration of general anaesthesias.
Lusedra is a proprietary water-soluble prodrug of propofol that is converted by alkaline phosphatase enzymes in the body after intravenous injection and is to be administered before sedative effects.
The product was approved in December 2008 by the Food and Drug Administration for use in patients undergoing diagnostic or therapeutic procedures.
In other Eisia news, the organisation revealed earlier this month that a trial into its metastatic breast cancer treatment E7389 (eribulin mesylate) achieved its primary endpoint.
As part of the study, 762 patients were administered either eribulin or one treatment of their choice - including single agent chemotherapy, hormonal treatment or biological therapy.
